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Asparaginase is an essential component of combination chemothera-py for childhood acute lymphoblastic leukemia and non-Hodgkinlymphoma. The value of asparaginase was further addressed in a
group of non-very high-risk patients by comparing prolonged (long-
asparaginase) versus standard (short-asparaginase) native E. coli asparaginase
treatment in a randomized part of the phase III 58951 trial of the European
Organization for Research and Treatment of Cancer Children’s Leukemia
Group. The main endpoint was disease-free survival. Overall, 1,552
patients were randomly assigned to long-asparaginase (775 patients) or
short-asparaginase (777 patients). Patients with grade ≥2 allergy to native E.
coli asparaginase were switched to equivalent doses of Erwinia or pegylated
E. coli asparaginase. The 8-year disease-free survival rate (±standard error)
was 87.0±1.3% in the long-asparaginase group and 84.4±1.4% in the short-
asparaginase group (hazard ratio: 0.87; P=0.33) and the 8-year overall sur-
vival rate was 92.6±1.0% and 91.3±1.2% respectively (hazard ratio: 0.89;
P=0.53). An exploratory analysis suggested that the impact of long-asparag-
inase was beneficial in the National Cancer Institute standard-risk group
with regards to disease-free survival (hazard ratio: 0.70; P=0.057), but far
less so with regards to overall survival (hazard ratio: 0.89). The incidences
of grade 3-4 infection during consolidation (25.2% versus 14.4%) and late
intensification (22.6% versus 15.9%) and the incidence of grade 2-4 allergy
were higher in the long-asparaginase arm (30% versus 21%). Prolonged
native E. coli asparaginase therapy in consolidation and late intensification
for our non-very high-risk patients did not improve overall outcome but led
to an increase in infections and allergy. This trial was registered at www.clini-
caltrials.gov as #NCT00003728.
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ABSTRACT
Introduction
The rate of success in the treatment of children with
acute lymphoblastic leukemia (ALL) and non-Hodgkin
lymphoblastic lymphoma (NHL) has increased steadily
since the 1970s. With contemporary risk-directed therapy
the 5-year overall survival rate is nowadays nearly 90%.1
This major improvement in outcome results from a better
understanding of the disease, more accurate stratification
according to prognostic risk factors and optimized drug
use. 
One of the essential components in treatment protocols
for childhood ALL and NHL is asparaginase (ASNase), an
enzyme that catalyzes serum asparagine and glutamine
deamination. In contrast to healthy cells, lymphoblasts are
unable to produce endogenous asparagine because of the
lack of the enzyme asparagine synthetase, and rely on
plasma levels of this amino acid for protein synthesis. A
depletion of plasma asparagine by ASNase results in selec-
tive apoptosis of lymphoblasts.2 The adverse effects of
ASNase are mainly related to disturbances in normal pro-
tein synthesis and to hypersensitivity reactions. 
Several study groups have demonstrated a benefit of
intensive ASNase treatment compared to less intensive
regimens.3-7 In the European Organization for Research
and Treatment of Cancer Children’s Leukemia Group
(EORTC-CLG) 58881 trial, our study group showed that
the use of a more potent ASNase with a longer half-life
improved patients’ outcome. Patients receiving native E.
coli ASNase 10,000 IU/m2 twice weekly in induction and
late intensification experienced longer event-free and
overall survival than patients randomized to Erwinia
ASNase at the same dosage and frequency.3,8 These results
were confirmed by the DFCI 95-01 trial for patients treat-
ed with 25,000 IU/m2 weekly of native E. coli or Erwinia
ASNase4. Both studies made clear that the use of native E.
coli ASNase was responsible for a reduction in relapse rate,
albeit resulting in more toxicity. Based on these studies
and data from pharmacokinetic and ASNase activity mon-
itoring, it is known that higher doses of Erwinia ASNase
and shorter dose intervals are required to achieve ASNase
activity that is adequate in comparison with that provided
by E. coli ASNase. Several study groups now incorporate
ASNase activity monitoring for the optimization of
ASNase therapy.
Not only do the formulation and dose of ASNase seem
to play a role, but the duration of the ASNase treatment
also has an impact on survival. The Italian, Dutch and
Hungarian IDH-ALL-91 trial demonstrated an improved
outcome for patients who received extended high-dose
native E. coli ASNase treatment in consolidation therapy
(25,000 IU/m2 weekly for 20 weeks) compared to the
same treatment based on a reduced-intensity Berlin-
Frankfurt-Münster (BFM)-backbone without extra
ASNase.5 The benefit of prolonged native E. coli ASNase
for T-cell ALL and NHL was also proven in the Pediatric
Oncology Group (POG) study 8704 in which a high-dose
ASNase regimen of 25,000 IU/m2 given weekly for 20
weeks starting from consolidation resulted in higher con-
tinuous complete remission rates.6 An increase in event-
free survival was also observed in the subsequent Dana
Farber Cancer Institute (DFCI) trial (ALL 91-01) as a result
of the prolongation of high-dose native E. coli ASNase
(25,000 IU/m2 weekly) or pegylated (PEG)-ASNase (2,500
IU/m2 every other week) for 20 to 30 weeks during inten-
sification therapy.7 However, patients were not random-
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Figure 1. General scheme of the EORTC-CLG 58951 trial. The EORTC-CLG trial 58951 embedded three main randomized comparisons: [R1] the value of prednisolone
(PRED, 60 mg/m²/day) versus dexamethasone (DEX, 6 mg/m²/day) in induction for all patients;12 [R2] the value of prolonged courses of ASNase throughout consol-
idation and late intensification for all non-very high risk (non-VHR) patients; and [R3] the value of vincristine (VCR) and corticosteroid pulses introduced in continuation
therapy for average risk (AR) patients.13 IA: induction phase; IB: consolidation phase; II A+B: late intensification phase; VCR: vincristine; VLR: very low risk (group); AR:
average risk (group); VHR: very high risk (group).
ized to a standard versus prolonged schedule of ASNase,
and the duration of ASNase was actually based on
ASNase tolerance.
In contrast, the controversy of intensified ASNase treat-
ment was highlighted in the Associazione Italiana Ematologia
e Oncologia Pediatrica (AIEOP) ALL-91 trial, in which high-
dose E. coli ASNase treatment (25,000 IU/m2 weekly for 20
weeks during late intensification and early continuation)
did not have an impact on disease-free survival compared
to standard E. coli ASNase treatment (4 doses of 10,000
IU/m2 during late intensification).9
The mode of administration (continuous or discontinu-
ous ASNase administration) may have different implica-
tions on  the development of ASNase hypersensitivity and
silent inactivation of ASNase. The probability of the
appearance of hypersensitivity reactions does not only
increase with the number of administrations within the
same cycle but also in discontinuous administration
schedules, in which ASNase is reintroduced after an
ASNase-free interval.10
Furthermore, more intensive ASNase therapy goes
along with an increase in ASNase-related toxicities. With
the advantages and side effects of ASNase in mind, the
optimal dosage and number of ASNase administrations
remain subject of debate. The EORTC-CLG, therefore,
conducted a randomized phase III trial 58951, comparing
a conventional native E. coli ASNase regimen with a pro-
longed native E. coli ASNase therapy in a BFM-based treat-
ment (Figure 1). 
Methods
Patients
As previously described,12,13 the EORTC-CLG 58951 protocol
included all children aged less than 18 years, with previously
untreated ALL of French-American-British (FAB) L1 or L2 mor-
phology whatever the immuno-phenotype, or precursor B- or T-
lymphoblastic NHL. Patients with ALL of FAB L3 morphology and
diffuse large cell B-cell lymphoma, Burkitt lymphoma or high-
grade B-cell lymphoma Burkitt-like, were excluded. Infants (<1
year) and patients with Philadelphia-positive ALL were allocated
to separate disease-specific protocols (Interfant protocol for infants
and Esphall protocol for Philadelphia-positive patients).
As described in the Online Supplementary Appendix, patients
were assigned to different risk groups: very low risk, average risk
low, average risk high and very high risk.12,13
Before entering the study, informed consent was obtained from
the parents or legal guardians according to the Declaration of
Helsinki. Both the EORTC Protocol Review Committee and the
local institutional ethical committees of each participating center
approved the study design.
Treatment and study design 
The EORTC-CLG 58951 study was based on a BFM-like proto-
col with a prephase, four-drug induction (IA), consolidation phase
(IB), interval phase with central nervous system-directed treat-
ment (without cranial radiotherapy), late intensification (IIA+B)
and maintenance therapy (Figure 1). Online Supplementary Table
S1A,B outlines the study design of the EORTC-CLG 58951 study
for the very low risk, average risk low and average risk high risk
groups.12,13
All non-very high-risk patients in complete remission or good
partial response at the end of induction were randomly assigned
to receive either conventional native E. coli ASNase therapy (12
doses, short-ASNase) or prolonged native E. coli ASNase therapy
(24 doses, long-ASNase) (Figure 1). Patients in the short-ASNase
arm had to receive 8x10,000 U/m2 in induction (IA) and
4x10,000 U/m2 in late intensification (IIA). The patients in the
long-ASNase arm had to receive 12 extra doses, 8x5,000 U/m2
native E.coli ASNase in consolidation (IB) and 4x5,000 U/m2 extra
doses in IIA. All native E.coli ASNase doses were scheduled
twice a week. Patients with grade ≥2 allergy to native E. coli
ASNase were switched to equivalent doses of Erwinia ASNase:
four doses of native E. coli ASNase (5,000 or 10,000 U/m2) were
replaced by six doses of 20,000 U/m2 Erwinia ASNase (3 per
week, in view of the shorter half-life). As Erwinia ASNase was
not available in Europe from the end of 2002 until 2006, patients
were, in that time period, switched to equivalent doses of pegy-
lated E. coli ASNase, and six doses of 20,000 U/m2 Erwinia
ASNase in 2 weeks substituted by one dose of 2,500 U/m2 of
pegylated E. coli ASNase (Table 1). 
Definitions
Definitions of central nervous system disease and complete
remission have been published previously12,13 and are summarized
in the Online Supplementary Appendix. Treatment-related toxicity
was graded according to the National Cancer Institute (NCI)
Common Toxicity Criteria version 1994.15
Statistical analysis
The primary endpoint of this study was disease-free survival,
secondary endpoints were overall survival and toxicity. In order to
detect an increase in the 5-year disease-free survival rate from
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Table 1. Native E.coli asparaginase administrations in different treatment cycles and switch to Erwinia or pegylated E.coli asparaginase in case
of grade 2 or more allergy.
Phase Native E.coli ASNase* Erwinia ASNase** Pegylated E.coli ASNase*
Induction (IA) 10,000 U/m2 x 8 20,000 U/m2 x 12 2,500 U/m2 x 2
Consolidation (IB)
Short-ASNase 0 0 0
Long-ASNase 5,000 U/m2x 8 20,000 U/m2 x12 2,500 U/m2 x 2
Late-intensification (IIA)
Short-ASNase 10,000 U/m2 x 4 20,000 U/m2 x 6 2,500 U/m2 x 1
Long-ASNase 10,000 U/m2 x 4 + 5,000 U/m2 x 4 20,000 U/m2 x 12 2,500 U/m2 x 2
Maintenance (only AR2) 25,000 U/m2 x 1 25,000 U/m2 x 2 2,500 U/m2 x 1
* intravenously. **intramuscularly or intravenously (on discretion of the treating physician). AR2: average risk high.
84% (short-ASNase arm) to 89% (long-ASNase arm), correspon-
ding to a treatment hazard ratio (HR) of 0.67, 1,500 patients had
to be randomized, of whom 212 had to be followed until an event
(log-rank test, 2-sided alpha=5%, power=80%). 
Further information on endpoint definitions, randomization
technique, stratification factors, and the statistical analysis16 is
included in the Online Supplementary Appendix.
Results
Patients’ characteristics
Between December 1998 and August 2008, 1,552 non-
very high-risk patients (1,481 with ALL and 71 with NHL)
were randomized in the EORTC-CLG trial 58951 to
receive either long-ASNase (n=775) or short-ASNase
(n=777). Of those patients 14.7% were very low risk,
66.2% average risk low and 19.1% average risk high
(Table 2). Twenty-nine (16 long-ASNase and 13 short-
ASNase) patients were considered a posteriori as being inel-
igible after randomization17,18 (Figure 2). The reasons for
ineligibility were: no complete remission/good partial
response (1 long-ASNase versus 3 short-ASNase), previous
toxicity (4 versus 2), very high risk (1 versus 6), minimal
residual disease ≥10-2 (10 versus 2). Nevertheless, those
patients were included in the disease-free survival and
overall survival analyses according to the intent-to-treat
principle. 
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Table 2. Patient and disease characteristics according to the native E. coli ASNase randomization.  
Long-ASNase Short-ASNase
n=775 n=777
N. of pts(%) N. of pts (%)
Type ALL 745 (96.1) 736 (94.7)
NHL 30 (3.9) 41(5.3)
Immunophenotype B-lineage 678 (87.5) 670 (86.2)
T-lineage 97 (12.5) 107 (13.8)
First randomization Prednisolone 389 (50.2) 389 (50.1)
Dexamethasone 383 (49.4) 382 (49.2)
Registered 3 (0.4) 6 (0.8)
Third randomization No pulses 99 (12.7) 94 (12.1)
Pulses 99 (12.7) 94 (12.1)
Not randomized 579 (74.6) 587 (75.8)
Sex Male 416 (53.7) 416 (53.5)
Female 359 (46.3) 361 (46.5)
Age (years) <1 4 (0.5) 0 (0)
1 - < 2 59 (7.6) 55 (7.1)
2 - < 6 409 (52.8) 381 (49.0)
6 - < 10 144 (18.6) 173 (22.3)
> 10 159 (20.5) 168 (21.6)
White blood cell count (x109/L) < 20 568 (73.3) 568 (73.1)
20- < 50 107 (13.8) 104 (13.4)
50 - < 100 52 (6.7) 55 (7.1)
> 100 48 (6.2) 50 (6.4)
NCI risk group* Standard risk 532 (68.6) 519 (66.8)
High risk 243 (31.4) 258 (33.2)
EORTC risk group VLR 113 (14.6) 114 (14.7)
AR1 514 (66.3) 514 (66.1)
AR2 148 (19.1) 149 (19.2)
Cerebrospinal fluid status CNS-1/TPL- 721 (93.0) 733 (94.3)
CNS-2/TLP+ 39 (5.1) 32 (4.1)
CNS-3 11 (1.4) 10 (1.3)
Missing 4 (0.5) 2 (0.3)
Response to prephase† “Poor response” 0 (0.0) 1 (0.1)
“Good response” 775 (100) 776 (99.9)
MRD at end of IA ≥ 10-2 22 (2.8) 13 (1.7)
10-3 - < 10-2 371 (47.9) 384 (49.5)
< 10-3 255 (32.9) 242 (31.1)
Missing 127 (16.4) 138 (17.7)
ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; NCI: National Cancer Institute; TLP-, traumatic lumbar puncture without blasts; TLP+, traumatic lumbar punc-
ture with blasts; CNS: central nervous system; VLR: very low risk; AR: average risk; AR1: averange risk low; AR2: average risk high; VHR: very high risk; MRD: minimal residual disease;
IA: induction; N: number of patients. *NCI Standard Risk: NHL or ALL with white blood cell count <50x109/L and age 1 - <10 years; NCI High Risk: NHL or ALL with white blood
cell count ≥50x109/L or age <1 or age ≥10 years. †Response to prephase (1 week prednisolone or dexamethasone and 1 intrathecal methotrexate): “poor response”: > 1x109
blasts/L, “good response”: < 1x109 blasts/L.  
The baseline characteristics of the patients and
leukemia, first randomization, response to prephase and
induction were evenly distributed in both treatment
groups (Table 2).
Treatment applicability
Among the 775 patients allocated to the long-ASNase
group, three patients never got the extra doses for
unknown reasons and received the short-ASNase arm. In
58 patients the long-ASNase was interrupted for various
reasons: relapse in 32, excessive toxicity in 17, parental
refusal in two, and other reasons in seven patients. 
Of the 777 patients allocated to the short-ASNase
group, two patients erroneously received the long-ASNase
treatment, and two did not receive the consolidation
block. In 50 patients ASNase was interrupted prematurely:
two because of failure to achieve remission, 34 because of
relapse, eight because of excessive toxicity, two because
of protocol violation and four for other reasons (Figure 2).
A total of 1,391 patients (641 treated with long-ASNase
and 750 with short-ASNase) received the total number of
administrations according to the protocol and randomiza-
tion arm. In the long-ASNase group, 103 (13.3%) patients
received an incomplete number of administrations and/or
insufficient dose of ASNase, while 13 (1.7%) of the 777
patients in the short-ASNase arm were undertreated.
Most of the protocol violations were due to a substitution
with insufficient amount and/or doses of Erwinia ASNase
(58 in the long-ASNase arm and 7 in the short-ASNase
arm) after allergic reactions to native E. coli ASNase.
Treatment results
At a 7-year median follow-up there were 97 events in
the long-ASNase arm and 111 in the short-ASNase group
(Table 3). The two patients in the short-ASNase group
who failed to achieve complete remission were consid-
ered as having had events at time 0. Relapse occurred in 87
children (11%) in the long-ASNase arm and in 102 chil-
dren (13%) in the short-ASNase arm. The site of relapse
for the long-ASNase versus short-ASNase comparison was
isolated bone marrow (54 versus 60), combined bone mar-
row (16 versus 23), isolated central nervous system (10 ver-
sus 11) and other isolated relapse (7 versus 8). Death in
complete remission occurred in ten children in the long-
ASNase arm and in seven children in the short-ASNase
arm. In the long-ASNase arm, three patients died of organ
toxicity, four due to an infection, one due to graft-versus-
host disease after hematopoietic stem cell transplantation
for a secondary myelodysplasia, one patient died of a pre-
existing cardiomyopathy during treatment and there was
one unexplained, sudden death during late intensification.
In the short-ASNase arm, one patient died due to organ
toxicity, two due to an infection, two due to a secondary
malignancy (1 central nervous system tumor and 1 medul-
loblastoma), one due to graft failure after hematopoietic
stem cell transplantation for a secondary acute myeloid
leukemia and one patient died of a pre-existing cardiomy-
opathy during treatment.
The 8-year disease-free survival rate (± standard error)
was 87.0±1.3% in the long-ASNase and 84.4±1.4% in
short-ASNase group (HR: 0.87; P=0.33) (Figure 3A). The 8-
year overall survival rate was comparable in the two treat-
ment arms: 92.6±1.0% in the long-ASNase group and
91.3±1.2% in the short-ASNase group (HR: 0.89; P=0.53)
(Figure 3B). Subgroup analyses according to immunophe-
notype, EORTC risk group and the steroid assigned during
induction (prednisolone versus dexamethasone) did not
reveal significant heterogeneity in the treatment differ-
ences regarding disease-free survival and overall survival
(Figures 4 and 5, Online Supplementary Figures S1-S3). In
contrast, in the NCI standard-risk ALL group, the long-
ASNase treatment had a positive effect [8-year disease-
free survival: 89.7% (long-ASNase) versus 85.0% (short-
ASNase), HR: 0.70; 99% confidence interval (CI): 0.44-
1.13; P=0.057] (Figure 4, Online Supplementary Figure S4A),
whereas in the NCI high-risk ALL group, a trend in the
opposite direction was observed (HR: 1.36; 99% CI: 0.77-
2.41; P=0.17) (Online Supplementary Figure S4C) (test for
heterogeneity: P=0.02). The favorable effect of long-
ASNase in this subgroup of patients was due to a
decreased number of bone marrow relapses (34 isolated or
combined bone marrow relapses versus 53 in the short-
ASNase group). The incidence of isolated central nervous
system (4 versus 5) and other isolated relapses (5 versus 6)
was equally low in both arms. In contrast, regarding over-
all survival, no treatment difference was noted in NCI
standard-risk (HR: 0.89) and high-risk ALL patients (Figure
5, Online Supplementary Figure S4B,D) (test for heterogene-
ity: P=0.52).
Restraining the treatment comparisons to eligible
patients only (n=1,523), in particular to those receiving
ASNase treatment according to the protocol guidelines
(n=1,391) and to those patients without grade 2-4 ASNase
allergy (n=1,154), similar results were obtained regarding
disease-free survival and overall survival (data not shown). 
Toxicity
The incidence of grade 3-4 infection was higher in the
long-ASNase group than in the short-ASNase group dur-
ing consolidation (25.2% versus 14.4%) and late intensifi-
cation (22.6% versus 15.9%). This difference was more
pronounced in patients who were randomly assigned to
dexamethasone in induction (Table 3).  
In both arms the incidence of grade 3-4 pancreatitis was
low (<2%) with a trend to a slightly higher incidence in
the long-ASNase group during consolidation (15 versus 4)
and late intensification (12 versus 3). Grade 2-4 allergy to
ASNase in the long-ASNase versus short-ASNase group
was 22.6% versus 0.2% during the consolidation phase
and 10.3% versus 21.4% in late intensification phase. In
the long-ASNase group, the incidence of grade 2-4 allergic
reactions was higher during consolidation (22.1%) than in
late intensification (10.3%). The type of corticosteroid
used in induction (prednisolone or dexamethasone) had
no impact on the incidence of allergy grade during consol-
idation or late intensification. During the whole treatment
period, the incidence of grade 2-4 allergy was 30.5% in the
long-ASNase arm and 21.7% in the short-ASNase arm. 
The incidences of other grade 3-4 toxicities reported
during consolidation and late intensification were similar
in the two randomization groups (Table 3).
Discussion
The prognosis of acute lymphoblastic malignancies has
been improved steadily by the use of multidrug
chemotherapy of which one of the key elements is
ASNase. Several contemporary collaborative studies have
demonstrated that intensification of ASNase therapy
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could offer an advantage in terms of outcome for the
patients. Nevertheless, extrapolation of these findings is
difficult as different dosages and sources of ASNase were
applied in different chemotherapy backbones. This was
the reason why the EORTC-CLG study group decided to
investigate the effect of extended native E. coli ASNase
therapy in consolidation and late intensification on top of
a BFM-backbone for all non-very high risk patients as one
of the randomized issues in the 58951 study.
We observed a slightly higher 8-year disease-free sur-
vival in the long-ASNase group (87.0% versus 84.4%; HR:
0.87; P=0.33) and a similar overall survival (92.6% versus
91.3%; HR: 0.89; P=0.53) rate in the long-ASNase group
compared to the short-ASNase group. The analogous out-
come rates  were confirmed in subgroup analysis accord-
ing to immunophenotype, EORTC risk group, and pred-
nisolone/dexamethasone randomization. Exploratory
analysis with an a posteriori classification of the ALL
patients according to NCI risk criteria showed a trend
towards higher 8-year disease-free survival rate for the
long-ASNase patients in the NCI standard-risk group due
to a lower number of bone marrow relapses. However,
the 8-year overall survival rate was comparable in the two
groups. Excluding patients who did not receive the
ASNase treatment as planned according to the allocated
arm or excluding allergic patients did not affect the dis-
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Figure 2. CONSORT statement in flow diagram.
ease-free survival rates. Our data are in accordance with
the results of the AIEOP ALL-91 study, in which no advan-
tage could be demonstrated for intermediate-risk patients
randomized to receive either standard treatment
(4x10,000 IU/m2 ASNase during late intensification) or
weekly high-dose ASNase 25,000 IU/m2 for 20 weeks dur-
ing late intensification and early continuation.9 The
International BFM study group showed in the IDH-ALL-
90 trial that extended high-dose native E. coli ASNase
(25,000 IU/m2 weekly for 20 doses, starting from the
beginning of continuation therapy) versus no ASNase
could improve outcome in standard-risk ALL patients
treated with a reduced-intensity BFM-based protocol. In
this protocol no consolidation block IB was given and two
doses of anthracyclines were omitted in late intensifica-
tion.5 Pession et al.5 postulated that the benefit obtained
from the extended native ASNase therapy in this study
probably overcame the reduced leukemia control by the
applied treatment reduction.
As in most BFM-based studies at that time, all EORTC-
CLG patients received classical doses of 10,000 IU/m2 of
native E. coli ASNase. For the additional doses in the long-
ASNase arm, patients received 5,000 IU/m2 of native E. coli
ASNase. The dose reduction was mainly dictated by the
fear of an excess in toxicity for those patients. Ahlke et al.
studied the pharmacokinetic and pharmacodynamic prop-
erties of different dosages of native E. coli ASNase. They
found that 96% of the patients had complete asparagine
depletion and sufficient native E. coli ASNase activity with
a dose of 5,000 IU/m2 every third day.19 This observation
gave sufficient evidence to apply a lower dosage of the
additional doses of native E. coli ASNase during consolida-
tion and late intensification in the long-ASNase group. As
previously reported by Domenech et al.,12 the number of
infections during induction was similar for the patients
treated with dexamethasone or prednisolone in the
EORTC-CLG 58951 trial. The concern of an excess in tox-
icity due to extended native E. coli ASNase use turned out
to be correct as patients in the long-ASNase arm had a
trend towards more grade 3-4 infections during consolida-
tion and late intensification, especially when they received
dexamethasone in induction. Others have reported that
dexamethasone was associated with a higher risk of infec-
tion during consolidation treatment, particularly in older
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Table 3. Outcome, type of event, and toxicity according to the randomized arm. 
Long ASNase Short ASNase
n=775 n=777
N. of pts (%) N. of pts (%)
Disease-free survival status No CR 0 (0) 2 (0.3)
CCR 678 (87.5) 666 (85.7)
Relapse 87 (11.2) 102 (13.1)
BM 54 (7.0) 60 (7.7)
CNS 10 (1.3) 11 (1.4)
Other isolated 7 (0.9) 8 (1.0)
BM+CNS 11 (1.4) 11 (1.4)
BM+other 5 (0.6) 10 (1.3)
BM+other+CNS 0 (0) 2 (0.3)
Death in CR 10 (1.3) 7 (0.9)
Survival status Alive 723 (93.3) 718 (92.4)
Dead 52 (6.7) 59 (7.6)
Toxicity Consolidation n=774 n=775
Grade 3-4 infection 195 (25.2) 112 (14.4)
PRED (n=776)                                           90 (11.6)                                                67 (8.6)
DEX    (n=764)                                           104 (13.6)                                                44 (5.8)
Grade 3-4 hyperglycemia 11 (1.4) 6 (0.8)
Grade 3-4 pancreatitis 15 (1.9) 4 (0.5)
Grade 3-4 thrombosis 9 (1.7) 7 (0.9)
Grade 3-4 hemorrhage 7 (0.9) 5 (0.6)
Grade 3-4 hepatotoxicity 152 (19.6) 136 (17.6)
Grade 2-4 allergy 174 (22.6) 2 (0.2)
Switch of asparaginase 172 (22.2) 4 (0.4)
Late Intensification n=738 n=748
Grade 3-4 infection 167 (22.6) 119 (15.9)
PRED (n=751) 81 (10.8) 67 (8.9)
DEX    (n=735) 86 (11.7) 52 (7.0)
Grade 3-4 hyperglycemia 30 (4.1) 22 (2.9)
Grade 3-4 pancreatitis 12 (1.6) 3 (0.4)
Grade 3-4 thrombosis 6 (0.8) 5 (0.7)
Grade 3-4 hemorrhage 4 (0.5) 3 (0.4)
Grade 3-4 hepatotoxicity 75 (10.2) 64 (8.6)
Grade 2-4 allergy 76 (10.3) 160 (21.4)
Switch of asparaginase 66 (8.9) 174 (23.3)
No CR: no complete remission; CCR: continuous complete remission; CNS: central nervous system; BM: bone marrow; PRED: prednisolone; DEX: dexamethasone; N: number of
patients.
children and adolescents.10,20 The excess in severe infec-
tions during consolidation and late intensification could be
the result of the additional myelosuppressive effect of pro-
longed administration of native E. coli ASNase in combina-
tion with intensive treatment10,21 and decreased
immunoglobulin production resulting from decreased pro-
tein synthesis. Although moderate, hematologic toxicity
from prolonged ASNase treatment might increase the
immunosuppressive effect of dexamethasone, especially
due to the fact that ASNase diminishes dexamethasone
clearance.22
As expected due to the longer exposure to the drug, the
cumulative incidence of grade 2-4 allergy was higher in
the long-ASNase arm than in the short-ASNase arm
(30.5% versus 21.7%). Although intermittent administra-
tion of native E. coli ASNase is considered to be a risk fac-
tor for allergy, our study demonstrated that the rate of
grade 2-4 allergic reactions in the long-ASNase arm was
higher in consolidation than in late intensification (22.1%
versus 10.3%). Concomitant administration of corticos-
teroids in late intensification reduces the risk of clinical
hypersensitivity reactions, whereas the protective effect
of the corticosteroids is absent in consolidation.2,23
Although concurrent administration of corticosteroids
reduces the clinical signs of allergic reactions, it does not
influence the neutralizing antibodies and the subsequent
inactivity of ASNase. It is known that not only the fre-
quency of allergy, but also the incidence of silent inactiva-
tion increases with longer duration of native E. coliASNase
exposure.  As native E. coli ASNase activity monitoring
was not performed in the EORTC 58951 trial, the inci-
dence of silent inactivation in this study remains unclear.
However, it is likely that the long treatment arm had more
silent inactivators who subsequently received insufficient
ASNase in the late intensification phase. The EORTC
58951 study ran in a period in which therapeutic drug
monitoring was not routinely performed to detect silent
inactivation and subtherapeutic asparaginase activity.
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Figure 3. (A) Disease-free survival and (B) over-
all survival according to the randomized arm. 
A
B
Nowadays it is well known that therapeutic drug monitor-
ing is essential in order to optimize asparaginase treat-
ment and therefore an increasing number of study groups
are including such monitoring in their study protocols.
Despite the fact that grade 3-4 pancreatitis was rare in
both treatment arms (<2%), there was a trend to a slightly
higher incidence among patients randomized to the long-
ASNase group. The incidences of other typical ASNase-
related grade 3-4 toxicities, such as hyperglycemia, throm-
bosis, hemorrhage and hepatotoxicity, were similar in the
two treatment groups.
Two large, randomized studies3,4 showed superiority of
native E. coli ASNase over Erwinia ASNase when given at
the same dose and frequency. In the EORTC-CLG trial
58881, 700 patients were randomized to receive either
native E. coli or Erwinia ASNase at a dosage of 10,000
IU/m2 twice weekly during induction and late intensifica-
tion. The patients randomized to receive Erwinia ASNase
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Figure 4. Forest plot regarding disease-free survival according to the randomization arm. ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; VL: very
low risk; AR1: average risk low; AR2: average risk high; DEX: dexamethasone; PRED: prednisolone; WBC: white blood cell count; NCI: National Cancer Institute; HR:
hazard ratio; CI: confidence interval.  *NCI Standard Risk: ALL with WBC <50x109/L and age 1 - <10 years; NCI High Risk: ALL with WBC ≥50x109/L or age <1 or age
≥10 years.
had lower 6-year event-free survival (59.8% versus 73.4%;
P=0.0004) and overall survival (75.1% versus 83.9%;
P=0.002) rates than those randomized to native E. coli
ASNase.3 In the DFCI 95-01 trial, 286 standard and high-
risk patients received either 25,000 IU/m2 weekly of native
E. coli or Erwinia ASNase. Patients treated with Erwinia
ASNase had an inferior 10-year event-free survival rate
(75.2% versus 84.6%; P=0.02) and overall survival rate
(85.3% versus 93.1%; P=0.04).4 In both studies, patients
treated with Erwinia ASNase experienced less toxicities
but more relapses,3,4 Although all patients in the EORTC-
CLG 58951 study received native E. coli ASNase as first-
V. Mondelaers et al.
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Figure 5. Forest plot regarding overall survival according to the randomization arm. ALL: acute lymphoblastic leukemia; NHL: non-Hodgkin lymphoma; VLR: very low
risk; AR1: average risk low; AR2: average risk high; DEX: dexamethasone; PRED: prednisolone; WBC: white blood cell count; NCI: National Cancer Institute; HR: hazard
ratio; CI: confidence interval. *NCI Standard Risk: ALL with WBC <50x109/L and age 1 - <10 years; NCI High Risk: ALL with WBC ≥50x109/L or age <1 or age ≥10
years. 
line treatment, a large proportion of the patients in the
long-ASNase arm had to be switched to Erwinia ASNase
due to allergic reactions. Based on the results of the
EORTC-CLG 58881 study, the subsequent 58951 trial rec-
ommended higher dosages of Erwinia ASNase (20,000
IU/m2 3 times a week) for patients with an allergic reac-
tion. Nevertheless, despite these dose recommendations
7.5% of patients in the long-ASNase group erroneously
received insufficient doses of Erwinia ASNase, which was
only the case in 0.9% of the patients assigned to short-
ASNase treatment. 
As already mentioned, at the start of the study, thera-
peutic drug monitoring of ASNase was not common prac-
tice in childhood ALL protocols. An increasing number of
study groups now incorporate the monitoring of ASNase
activity to optimize treatment efficacy. It is widely accept-
ed that ASNase activity is optimal if trough activity levels
are >100U/L.2 A recent DCOG study highlighted the short
activity of Erwinia ASNase by measuring trough levels of
ASNase activity. Effective ASNase activity levels were
found in 100% (at 48 h) and 33% (at 72 h) of patients
treated with 20,000 IU Erwinia ASNase twice or three
times a week.24 In our study, allergic patients received
Erwinia ASNase three times a week, mostly on Monday,
Wednesday and Friday. Although ASNase monitoring was
not routinely performed in our study, extrapolating the
data of Tong et al. we assume that at least some of our
patients receiving Erwinia ASNase were undertreated dur-
ing the weekend. 24This, together with the fact that fewer
patients in the long-ASNase arm received all intended
doses as planned in the protocol, could mitigate the poten-
tial benefit of prolonged ASNase treatment. Moreover,
prolonged native E. coli ASNase therapy resulted in an
increase in allergic reactions, pancreatitis and infections
which can hamper the treatment efficacy by omission or
delay of other essential chemotherapeutics.
It is important to note that ASNase therapy in our study
consisted of treatment for 12 weeks in the long-ASNase
arm versus 6 weeks in the short arm, given in a discontin-
uous way. Our extended arm is not comparable with the
very prolonged and continuous use of ASNase (30 weeks)
in the DCOG and DFCI protocols. In the DCOG ALL10
protocol, patients with medium risk according to minimal
residual disease received therapy intensification including
30 weeks of PEG-ASNase exposure and dexamethasone/
vincristine pulses. This resulted in a significantly higher 5-
year event-free survival rate compared with that in histor-
ical controls (88% versus 76%; P=0.056).25 An increase in
event-free survival was also observed in the DFCI ALL 91-
01 trial for patients who tolerated prolonged high-dose
native E. coli ASNase (25,000 IU/m2 weekly) or PEG-
ASNase (2,500 IU/m2 every other week) for 30 weeks
compared to patients who tolerated less than 20 weeks of
extended ASNase therapy.7 The relatively short extension
of ASNase treatment in our trial together with the
increased risk of silent inactivation and allergy due to the
discontinuous administrations, may have nullified the
effect seen in the very prolonged, continuous schedules of
the DCOG and DFCI protocols. Moreover, we used native
E. coli ASNase, which is being increasingly replaced by
PEG-ASNase in contemporary childhood ALL trials, due
to the longer action and the lower incidence of allergy and
silent inactivation.  
In conclusion, this study demonstrates that a 6-week
prolongation of native E. coli ASNase therapy in a discon-
tinuous administration schedule (during consolidation
and late intensification) does not significantly improve
patients’ overall outcome. Our study underscores the
hypothesis of Pession that the overall treatment intensity
of this BFM-based regimen, with four-drug induction for
all patients, already results in maximal therapeutic effica-
cy, whereas intensification with prolonged native E. coli
ASNase therapy does not add any benefit for these
patients.5 One has to be cautious to extrapolate our
results to other studies especially if less intensive induc-
tion therapy, other asparaginase preparations or other
administration schedules are used. Future studies should
aim to optimize the efficacy of ASNase therapy, not only
by prolonged administration but by the use of PEG-
ASNase and by therapeutic drug monitoring in real time
in order to promptly intercept silent inactivation and sub-
therapeutic asparaginase activity.
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